{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:28:13Z","timestamp":1786573693206,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor\u2013positive\/Human epidermal growth factor receptor 2\u2013negative (HR+\/HER2\u2013) early breast cancer accounts for the majority of breast cancer cases. Although chemotherapy can reduce recurrence risk, its use in HR+\/HER2\u2013 high-risk disease remains complex in clinical practice. We aimed to examine regional variation in chemotherapy use in Sweden and its association with prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this population-based cohort study, we included 61,935 women diagnosed with HR+\/HER2\u2013 early breast cancer between 2007 and 2023, identified through the Swedish National Quality Register for Breast Cancer. Multivariable logistic regression was applied to identify factors that were associated with chemotherapy use across the Swedish healthcare regions. Overall survival was analysed using Kaplan\u2013Meier estimates and regression standardisation based on Cox models, adjusting for clinicopathological and socioeconomic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Chemotherapy was administered to 28\u00b70% of patients, with substantial regional variation (range 23\u00b70\u201334\u00b77%). Younger age, larger tumour size, node-positive disease, and higher tumour grade were associated with chemotherapy use. Regional differences in 10-year all-cause mortality persisted after adjustment among patients aged\u2009\u2265\u200965\u00a0years but were minimal among those aged\u2009&lt;\u200965\u00a0years. The healthcare region with the highest chemotherapy use had the lowest mortality. Socioeconomic factors did not alter these associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Chemotherapy use in patients with HR+\/HER2\u2013 early breast cancer varies across the Swedish healthcare regions despite common guidelines. Among young and middle-aged patients, these differences were not associated with survival disparities. In contrast, among patients aged\u2009\u2265\u200965\u00a0years, regional differences in treatment remained associated with differences in prognosis also after socioeconomic adjustments, suggesting undertreatment in some regions. These findings support continued efforts to harmonize implementation of treatment recommendations to ensure equitable care for patients with HR+\/HER2\u2009\u2212\u2009early breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02366-w","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:04:27Z","timestamp":1786572267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+\/HER2- early breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Balazs","family":"Acs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Gkekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L. V.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Foukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2366_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.breast.2021.02.009","volume":"57","author":"EM Salvo","year":"2021","unstructured":"Salvo EM, Ramirez AO, Cueto J, et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast (Edinburgh). 2021;57:5\u201317.","journal-title":"Breast (Edinburgh)"},{"issue":"19","key":"2366_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2366_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"issue":"9814","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432\u201344.","journal-title":"Lancet"},{"issue":"11","key":"2366_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.annonc.2025.08.002","volume":"36","author":"N Chen","year":"2025","unstructured":"Chen N, Freeman JQ, Yarlagadda S, et al. Impact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer. Ann Oncol. 2025;36(11):1356\u201365.","journal-title":"Ann Oncol"},{"issue":"12","key":"2366_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003006","volume":"16","author":"E Gray","year":"2019","unstructured":"Gray E, Marti J, Wyatt JC, Brewster DH, Hall PS. Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: a retrospective cohort study. PLoS Med. 2019;16(12):e1003006.","journal-title":"PLoS Med"},{"issue":"2","key":"2366_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"2366_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2017.74.6586","volume":"36","author":"AV L\u00e6nkholm","year":"2018","unstructured":"L\u00e6nkholm AV, Jensen MB, Eriksen JO, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018;36(8):735\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2366_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41523-022-00394-1","volume":"8","author":"K Iles","year":"2022","unstructured":"Iles K, Roberson ML, Spanheimer P, et al. The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment. NPJ Breast Cancer. 2022;8(1):27.","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10654-025-01226-9","volume":"40","author":"JF Ludvigsson","year":"2025","unstructured":"Ludvigsson JF, Bergman D, Lundgren CI, et al. The healthcare system in Sweden. Eur J Epidemiol. 2025;40(5):563\u201379.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"2366_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12889-019-6846-6","volume":"19","author":"L L\u00f6fgren","year":"2019","unstructured":"L\u00f6fgren L, Eloranta S, Krawiec K, et al. Validation of data quality in the Swedish National Register for Breast Cancer. BMC Public Health. 2019;19(1):495.","journal-title":"BMC Public Health"},{"issue":"12","key":"2366_CR12","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1158\/1055-9965.EPI-05-0317","volume":"14","author":"S Eaker","year":"2005","unstructured":"Eaker S, Dickman PW, Hellstr\u00f6m V, Zack MM, Ahlgren J, Holmberg L. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2914\u20138.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10 Pt A","key":"2366_CR13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.ejso.2020.04.030","volume":"46","author":"D Unukovych","year":"2020","unstructured":"Unukovych D, G\u00fcm\u00fcsc\u00fc R, W\u00e4rnberg F, et al. Breast reconstruction patterns from a Swedish nation-wide survey. Eur J Surg Oncol. 2020;46(10 Pt A):1867\u201373.","journal-title":"Eur J Surg Oncol"},{"key":"2366_CR14","first-page":"149","volume":"112","author":"L Adwall","year":"2025","unstructured":"Adwall L, Fredriksson I, Hultin H, et al. Major systemic infection following breast cancer surgery associated with worse oncological outcomes. Br J Surg. 2025;112:149\u2013224.","journal-title":"Br J Surg"},{"issue":"4","key":"2366_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Ol\u00e9n O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research: JF Ludvigsson et al. Eur J Epidemiol. 2019;34(4):423\u201337.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"2366_CR17","unstructured":"The Swedish National guidelines for the treatment of breast cancer. https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/brostcancer\/vardprogram\/ 2025."},{"key":"2366_CR18","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2025","unstructured":"Brierley JD, Giuliani M, O\u2019Sullivan B, Rous B, Van Eycken E. TNM classification of malignant tumours. John wiley & sons; 2025."},{"issue":"27","key":"2366_CR19","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023;41(27):4433\u201342.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2366_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1027\/1614-2241.1.3.86","volume":"1","author":"CJ Maas","year":"2005","unstructured":"Maas CJ, Hox JJ. Sufficient sample sizes for multilevel modeling. Methodology. 2005;1(3):86\u201392.","journal-title":"Methodology"},{"issue":"4","key":"2366_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/EDE.0b013e3181caeb90","volume":"21","author":"AE Hubbard","year":"2010","unstructured":"Hubbard AE, Ahern J, Fleischer NL, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21(4):467\u201374.","journal-title":"Epidemiology"},{"issue":"1","key":"2366_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","volume":"2","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Austin PC, Lee DS, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2(1):88\u201393.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2366_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12913-018-3210-y","volume":"18","author":"N Johansson","year":"2018","unstructured":"Johansson N, Jakobsson N, Svensson M. Regional variation in health care utilization in Sweden - the importance of demand-side factors. BMC Health Serv Res. 2018;18(1):403.","journal-title":"BMC Health Serv Res"},{"key":"2366_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2019.102254","volume":"71","author":"A God\u00f8y","year":"2020","unstructured":"God\u00f8y A, Huitfeldt I. Regional variation in health care utilization and mortality. J Health Econ. 2020;71:102254.","journal-title":"J Health Econ"},{"issue":"6","key":"2366_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10654-016-0157-3","volume":"31","author":"A Sj\u00f6lander","year":"2016","unstructured":"Sj\u00f6lander A. Regression standardization with the R package stdReg. Eur J Epidemiol. 2016;31(6):563\u201374.","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"2366_CR26","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41416-022-01949-6","volume":"127","author":"E Syriopoulou","year":"2022","unstructured":"Syriopoulou E, W\u00e4sterlid T, Lambert PC, Andersson TML. Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data. Br J Cancer. 2022;127(10):1808\u201315.","journal-title":"Br J Cancer"},{"issue":"2","key":"2366_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcpo.2014.01.003","volume":"2","author":"B J\u00f6nsson","year":"2014","unstructured":"J\u00f6nsson B, Wilking N. New cancer drugs in Sweden: assessment, implementation and access. J Cancer Policy. 2014;2(2):45\u201362.","journal-title":"J Cancer Policy"},{"key":"2366_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100331","author":"E Gray","year":"2021","unstructured":"Gray E, Figueroa JD, Oikonomidou O, et al. Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open. 2021. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100331.","journal-title":"ESMO Open"},{"key":"2366_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103741","volume":"76","author":"S Hosseini-Mellner","year":"2024","unstructured":"Hosseini-Mellner S, Wickberg \u00c5, Karakatsanis A, Valachis A. Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive \/ HER2-negative breast cancer: a propensity score matching population-based study. Breast. 2024;76:103741.","journal-title":"Breast"},{"key":"2366_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2340\/1651-226X.2024.40575","volume":"63","author":"A De Jong","year":"2024","unstructured":"De Jong A, Von Wachenfeldt A, Nystr\u00f6m L, Andersson A. Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. Acta Oncol. 2024;63:901\u20138.","journal-title":"Acta Oncol"},{"issue":"1","key":"2366_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.annonc.2021.09.007","volume":"33","author":"Y Wang","year":"2022","unstructured":"Wang Y, Acs B, Robertson S, et al. Improved breast cancer histological grading using deep learning. Ann Oncol. 2022;33(1):89\u201398.","journal-title":"Ann Oncol"},{"key":"2366_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100662","volume":"11","author":"T Ruelle","year":"2026","unstructured":"Ruelle T, Grinda T, Del Mastro L, Lacroix-Triki M, Pistilli B, Gessain G. How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer. ESMO Real World Data Digit Oncol. 2026;11:100662.","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"8","key":"2366_CR33","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30\u201366.","journal-title":"Circulation"},{"issue":"3","key":"2366_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","volume":"164","author":"SAM Gernaat","year":"2017","unstructured":"Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2366_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/joim.70029","volume":"298","author":"J Fritzell","year":"2025","unstructured":"Fritzell J, Fors S. Health inequalities in the Nordic countries: a comparative overview and update. J Intern Med. 2025;298(6):591\u2013603.","journal-title":"J Intern Med"},{"issue":"9","key":"2366_CR36","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.29967","volume":"138","author":"KD Skyrud","year":"2016","unstructured":"Skyrud KD, Bray F, Eriksen MT, Nilssen Y, M\u00f8ller B. Regional variations in cancer survival: impact of tumour stage, socioeconomic status, comorbidity and type of treatment in Norway. Int J Cancer. 2016;138(9):2190\u2013200.","journal-title":"Int J Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02366-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02366-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02366-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:04:29Z","timestamp":1786572269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02366-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02366-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee at Karolinska Institutet, Stockholm, Sweden and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B. Acs declares receiving honoraria from Pfizer, Need.AI, Daiichi Sankyo, AstraZeneca. JH has obtained speaker\u2019s honoraria or advisory board remunerations from Gilead, Novartis, Pfizer, EliLilly, MSD, AstraZeneca, Sakura, Hologic and has received institutional research support from MSD and AstraZeneca. JH is co-founder and shareholder of Stratipath AB. P. Karlsson reports on advisory role\/lectures: Astrazeneca, Lilly, Novartis, MSD, Roche, Pfizer, contracts regarding biomarkers: Prelude Dx, Exact Sciences. IF has received institutional research grants from MSD for research projects performed under the Master Collaboration Agreement between MSD and Karolinska Institutet, unrelated to this work. Theodoros Foukakis: invited Speaker, Payment to Institution: Roche, Astra Zeneca, Gilead Sciences, Novartis, Daiichi Sankyo, Bristol Myers Squibb; royalties, personal: Wolters Kluwer (authorship of two chapters in UpToDate); clinical trial support to Institution: Astra Zeneca, Coordinating PI (research grant and study drug), Novartis, Coordinating PI (research grant and study drug), Veracyte, Coordinating PI (discount on the ProsignaPAM50 assay in ARIADNE clinical trial). Antonis Valachis has received institutional unrestricted research grant from Roche and MSD unrelated to the current work and institutional payment for lectures from Daiichi-Sankyo, Pfizer, Novartis, MSD, AstraZeneca.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"139"}}